ENDPOINTS

Anti-aging biotech NewLimit raises $130M Series B round

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, has raised a $130 million Series B round to get its lead drug candidates closer to human testing. The South San Francisco-based biotech announced ...

May 6, 2025 - 16:03
 0
Anti-aging biotech NewLimit raises $130M Series B round
NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, has raised a $130 million Series B round to get its lead drug candidates closer to human testing. The South San Francisco-based biotech announced ...
Read More

Tags:

Previous Article

Vertex pauses study of mRNA therapy for cystic fibrosis

Next Article

Validating, Standardizing, and Accelerating Healthcare Applications on Mayo Clin...

Related Posts

Lilly asks EU regulator to revisit Kisunla; CHMP recommends PTC's PKU drug

Lilly asks EU regulator to revisit Kisunla; CHMP recomm...

Apr 25, 2025  0

Avidicure's $50M seed round; Flagship's new AI company that detects disease

Avidicure's $50M seed round; Flagship's new AI company ...

Apr 24, 2025  0

Singapore cardio gene therapy biotech collects $45M as it plots Europe expansion

Singapore cardio gene therapy biotech collects $45M as ...

May 6, 2025  0